WallStreetWisdom
-
Cramer’s Buy Calls Aren’t Alpha — They’re Exit Liquidity
Jim Cramer says buy Marvell and Bausch Health. The real question isn’t whether he’s bullish — it’s whether you should be. Because in 2024, a Cramer buy call isn’t just a recommendation. For some traders, it’s a contrarian indicator. Let’s break this down. Marvell (MRVL): AI Tailwinds — But You’re Paying for Them Marvell is…
-
If Jim Cramer Loves It, You’d Better Check the Exit
Jim Cramer said buy it. So now what? That’s the question every trader should ask when a TV personality pounds the table on a stock. Not because Cramer’s always wrong — he’s not. But because once something becomes a headline trade, the easy money is usually gone. Right now, that tension is playing out in…
-
Buffett Isn’t Chasing Oil Hype — He’s Betting on Scarcity
When Warren Buffett keeps buying oil, you pay attention. When he buys the chemical arm too, you really pay attention. Berkshire Hathaway now owns roughly 28% of Occidental Petroleum’s common stock — and about 32.7% if you include the warrants sitting in Buffett’s back pocket. In January, Berkshire closed its $9.7B acquisition of OxyChem, Occidental’s…
-
VOO Wins Because It Refuses to Entertain You
**VOO isn’t exciting. That’s exactly why it keeps winning.** If you’re looking for drama, VOO (Vanguard’s S&P 500 ETF) is the wrong ticker. No meme-stock chaos. No “next Nvidia” dreams. Just America’s 500 biggest companies, bundled together, quietly compounding like a machine. And in 2024–2025, that boring formula has absolutely crushed it. Here’s the thesis…
You must be logged in to post a comment.